Quantcast

Latest Immunosuppressants Stories

2014-04-28 12:31:12

- Study published online in Liver Transplantation - HORSHOLM, Denmark, April 28, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the publication of a Phase II study demonstrating conversion from twice-daily tacrolimus to once-daily Envarsus(®) in stable liver transplant patients in Liver Transplantation. Key points: -- Envarsus(®) is an extended release formulation of tacrolimus designed for once-daily dosing, flatter pharmacokinetics and greater...

2014-04-28 12:27:09

Rheumatologists Cite Improved Health-Related Quality of Life, Improved Effect in Disease Activity among Unmet Needs, According to Findings from Decision Resources Group BURLINGTON, Mass., April 28, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and EU5 rheumatologists agree that new therapies for the treatment of moderate to severe systemic lupus erythematosus (SLE) that offer improved effect on disease activity and renal organ domain scores over current therapies...

2014-04-23 12:29:37

New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma Major, Lupin Limited (Lupin) announced today that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo) to create a new entity, YL Biologics (YLB). YLB will be jointly managed by both partners and will be responsible for conducting...

2014-04-20 23:01:04

ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report in its store. Dallas, TX (PRWEB) April 20, 2014 Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report says that over the last decades, therapeutic options for Plaque...

2014-04-17 23:07:50

New webinar will focus on scientific and process improvements that advance Rheumatoid Arthritis (RA) drug development. This live discussion takes place on Wednesday, May 7, 2014 at 10:00am EDT (15:00 UK BST/ GMT +1). Toronto, Canada (PRWEB) April 17, 2014 Rheumatoid Arthritis (RA) is a complex and heterogeneous disease that has the potential to significantly impact morbidity, mortality and quality of life while also placing a substantial burden on healthcare systems globally. While...

2014-04-16 16:30:36

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_global_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022 SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged...

2014-04-16 16:26:34

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_atopic_dermatitis_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Atopic Dermatitis - US Drug Forecast and Market Analysis to 2022SummaryAlthough the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated,...

2014-04-15 12:30:07

Potential U.S. Commercialization in 2014 CHICAGO, April 15, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the name Rasuvo(TM) for the company's lead compound, MPI-2505, a subcutaneous injectable methotrexate (MTX) delivered in a ready-to-use autopen. Currently under...

2014-04-04 12:27:14

FLINT, Mich., April 4, 2014 /PRNewswire-iReach/ -- Diplomat has announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla® (apremilast), a new medication for the treatment of psoriatic arthritis. Otezla® is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla® was approved by the FDA on March 21, 2014, and is available in 10 mg, 20 mg and 30 mg tablets. Diplomat...

2014-03-28 12:21:53

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/lwpmln/investigation ) has announced the addition of the "Investigation Report on China Tacrolimus Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Tacrolimus, also named as ""FK506"" and ""FR-900506"", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co.,...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'